A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-14 and is reviewed periodically as new material appears.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
The times are half-lives The second isotope 242Am was produced upon neutron bombardment of the already-created 241Am. Upon rapid β-decay, 242Am converts into the isotope of curium 242Cm (which had been discovered previously). The half-life of this decay was initially determined at 17 hours, which was close to the presently accepted value of 16.02 h.
Ciglitazone (INN) is a thiazolidinedione. Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market. Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome. Ciglitazone is a potent and selective PPARγ ligand. It binds to the PPARγ ligand-binding domain with an EC50 of 3.0 μM. Ciglitazone is active in vivo as an anti-hyperglycemic agent in the ob/ob murine model. Inhibits HUVEC differentiation and angiogenesis and also stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.
The human body produces diverse surfactants. Pulmonary surfactant is produced in the lungs in order to facilitate breathing by increasing total lung capacity, and lung compliance. In respiratory distress syndrome or RDS, surfactant replacement therapy helps patients have normal respiration by using pharmaceutical forms of the surfactants. One example of a pharmaceutical pulmonary surfactant is Survanta (beractant) or its generic form Beraksurf, produced by Abbvie and Tekzima respectively. Bile salts, a surfactant produced in the liver, play an important role in digestion. Certain caterpillars (of the moth species Spodoptera exigua, South East Asia) spit a surfactant-containing secretion at predators. This deters attacking ants, allowing the caterpillars to escape. The surfactants in the caterpillars' oral secretions reduce its surface tension. Instead of rolling off the ants' water-repellent skin like normal water, the secretion soaks the attackers. The affected ants then clean themselves, which gives the caterpillar enough time to escape.
By the time of the Civil War, the mansions and shops had given way to popular music halls, brothels, beer gardens, pawn shops, and flophouses, like the one at No. 15 where the composer Stephen Foster lived in 1864. Theodore Dreiser closed his tragedy Sister Carrie, set in the 1890s, with the suicide of one of the main characters in a Bowery flophouse. The Bowery, which marked the eastern border of the slum of "Five Points", had also become the turf of one of America's earliest street gangs, the nativist Bowery Boys. In the spirit of social reform, the first YMCA opened on the Bowery in 1873; another notable religious and social welfare institution established during this period was the Bowery Mission, founded in 1880 at 36 Bowery by Reverend Albert Gleason Ruliffson. The mission has remained along the Bowery throughout its lifetime. In 1909 the mission moved to its current location at 227–229 Bowery. By the 1890s, the Bowery was a center for prostitution that rivaled the Tenderloin, also in Manhattan, and for bars catering to gay men and some lesbians at various social levels, from The Slide at 157 Bleecker Street, New York's "worst dive", to Columbia Hall at 5th Street, called Paresis Hall. One investigator in 1899 found six saloons and dance halls, the resorts of "degenerates" and "fairies", on the Bowery alone. Gay subculture was more highly visible there and more integrated into working-class male culture than it became in the following generations, according to historian George Chauncey.
== Example == The decay correct might be used this way: a group of 20 animals is injected with a compound of interest on a Monday at 10:00 a.m. The compound is chemically joined to the isotope copper-64, which has a known half-life of 12.7 hours, or 764 minutes. After one hour, the 5 animals in the "one hour" group are killed, dissected, and organs of interest are placed in sealed containers to await measurement. This is repeated for another 5 animals, at 2 hours, and again at 4 hours. At this point, (say, 4:00 p.m., Monday) all the organs collected so far are measured for radioactivity (a proxy of the distribution of the compound of interest). The next day (Tuesday), the "24 hour" group would be killed and dissected at 10:00 a.m., then measured for radioactivity, (say at 11:00 a.m.). In order to compare ALL the groups together, the data from the "24 hour" must be decay corrected: the radioactivity measured on the second day must be "adjusted" in order to allow a comparison to measurements from an earlier time, but of the same original material. In this case, "time zero" is Monday, 4:00 p.m., when the first three groups (1,2, and 4 hour animals organs) were measured. The "24 hour" group was measured at 11:00 a.m. Tuesday, which is 19 hours after the first groups. Start by calculating the decay constant "K". Substitute 12.7 (hours, the half-life of copper-64) for
Sources: en.wikipedia.org
Treatment of intraarticular fracture usually falls into conservative (nonsurgical) or surgical management depending on the degree of displacement or movement of the fractured piece from native alignment. Treatment often relies on fracture reduction with use of sedation or local anesthetic to attempt to reset the alignment into tolerances that favor bone healing. This is often done in an emergency room setting or clinic and the patient may be placed into an immobilization device such as a splint or cast to allow time for healing. Surgical intervention is most common in cases of intraarticular fractures because it allows direct visualization of the joint surface to help mediate chances of posttraumatic osteoarthritis. Risks of surgical intervention include blood loss, infection, and problems with wound healing. Most commonly, open reduction internal fixation (ORIF) is the modality used which utilizes plates and screws to restore alignment of the fracture. Recently, there has been a push for minimally invasive options, such as percutaneous pinning, secondary to wound complications with use of ORIF. With pinning, intraoperative radiography is used to drive screws through the skin. However, with this technique, there continues to be some risk of posttraumatic arthritis due to the joint surface not being viewed during operation. Even with perfect joint alignment there continues to be a risk of posttraumatic arthritis.
The National Center for Complementary and Integrative Health (NCCIH) is a United States government agency which explores complementary and alternative medicine (CAM). It was created in 1991 as the Office of Alternative Medicine (OAM), and renamed the National Center for Complementary and Alternative Medicine (NCCAM) before receiving its current name in 2014. NCCIH is one of the 27 institutes and centers that make up the National Institutes of Health (NIH) within the United States Department of Health and Human Services. NCCIH has been criticized for funding and marketing pseudoscientific medicine and quackery.
Antibody–drug conjugates or ADCs are a class of bioconjugates and immunoconjugates. ADCs are composed of an antibody linked to a cytotoxic (anticancer) "payload" or drug. Among treatment options for cancer, chemotherapy is most widely used. Its main limitation is low target specificity. Unlike chemotherapy, ADCs target tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs. ADCs combine the targeting properties of monoclonal antibodies with the cancer-killing capabilities of cytotoxic drugs, designed to discriminate between healthy and diseased tissue.
Chiedozie Ngozi Egesi is a Nigerian plant scientist and professor. He is director of numerous research projects dedicated to international agriculture, gender equity and food and nutrition security in agriculture. He received the Achiever in Agriculture Award in 2021 by the Nigeria Agriculture Awards in 2021 and the Kwame Nkrumah Leadership Prize in 2022. Egesi grew up in a farming community in Umuahia South, Abia State. He received a Bachelor of Science from the University of Calabar in 1994 and a Master in Science on Environmental Biology at University of Ibadan in 1997. He earned a Ph.D in Agricultural Biology from University of Ibadan in 2001 He took certificate courses on Statistical Genetics at the University of Washington, Seattle, USA in 2007 and Spring class on Qualitative Trait Loci Analyses and Statistical Genetics at the Cornell University Ithaca, New York in April, 2012.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.